Results 61 to 70 of about 1,936 (153)

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions

open access: yes
Background Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges.
Fu, Ying   +13 more
core   +1 more source

Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital [PDF]

open access: yes, 2019
Objectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrug resistant (MDR) and extensively drug-resistant (XDR) non metallo-ß-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital ...
Rezusta Lopez, Antonio   +8 more
core  

Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria

open access: yesJournal of Microbiology, Immunology and Infection, 2019
Background: Complicated urinary tract infection (cUTI) is often associated with drug-resistant pathogens and requires therapy with broad-spectrum antibiotics.
Guan-Jhou Chen   +5 more
doaj   +1 more source

Case Report: Sepsis With Multisystemic Amyloid Light‐Chain Amyloidosis

open access: yesCase Reports in Critical Care, Volume 2026, Issue 1, 2026.
Introduction Systemic light‐chain (AL) amyloidosis is a complex disorder characterized by extracellular fibril deposition, leading to severe multisystem dysfunction. When sepsis superimposes on preexisting organ impairment, early clinical recognition becomes particularly challenging yet critical.
Mehtap Selçuk   +4 more
wiley   +1 more source

Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study

open access: yes, 2019
Objectives: Published in vitro stability data for ceftolozane-tazobactam supports intermittent short duration infusions. This method of delivery is not feasible for many outpatient antimicrobial therapy services that provide only one or two visits per ...
Raby, Edward   +6 more
core   +1 more source

Beyond the Diagnosis: A Comprehensive Case Report on Duchenne Muscular Dystrophy

open access: yesCase Reports in Critical Care, Volume 2026, Issue 1, 2026.
Background Duchenne muscular dystrophy (DMD) is an X‐linked recessive genetic disorder characterized by the absence of dystrophin, leading to progressive muscle degeneration and generalized weakness. It primarily affects males in early childhood and progresses to loss of ambulation and cardiac and respiratory complications. Case Report This case report
Mahmoud Abdel Hameed Shahin   +9 more
wiley   +1 more source

Comparative effectiveness of ceftolozane/tazobactam relative to ceftazidime/avibactam for the treatment of adult, hospitalized patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa in U.S. Veterans Health Administration facilities

open access: yesAntimicrobial Agents and Chemotherapy
Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (C/A) are frequently used for the treatment of multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) pneumonia. However, comparative “real-world” effectiveness data are limited.
Nicholas S. Britt   +4 more
doaj   +1 more source

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2018
Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials.
Golub A.V., Kozlov R.S.
doaj   +1 more source

Candidemia Complicated by Mycotic Thrombus of the Femoral Artery in a Patient With Left Ventricular Assist Device

open access: yesCase Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Background Ventricular assist devices (VADs) are increasingly used as a bridge to transplantation or as destination therapy in heart failure patients. Fungal bloodstream infections, though less common than bacterial infections in VAD recipients, carry the highest mortality.
Francesco Siviero   +13 more
wiley   +1 more source

A Rare Case of Prosthetic Joint Infection Caused by Group D Salmonella

open access: yesCase Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Prosthetic joint infections (PJIs) are gaining growing attention as a healthcare issue. Salmonella spp. is a rare cause of PJI, mostly involving hip arthroplasty rather than knee arthroplasty. Therefore, clinical experience on the management of PJI involving knee arthroplasties caused by Salmonella spp. is scant.
Anna Barbiero   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy